Regulatory submission is based on positive results from the Phase 2 PROSPECT Study —– FDA sets PDUFA Date of December 18, 2026 —OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera ...

The FDA accepted filing for a new drug application (NDA) today for tirabrutinib for the treatment of adults with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL), according ...

(Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States ...

More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

Registration is now open for the “New Developments in PCNSL Treatment” online educational event on March 27th, 2026, ...

Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a ...

Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Deciphera Pharmaceuticals, Inc. (DCPH) been one of those stocks this year? By ...

Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...